| HOME >> BIOLOGY >> TECHNOLOGY |
Andrew Limpert, interim CEO of BBM stated: "We believe a combined BBM and YMI will make a powerful Biotech combination. The scientific synergies and collective management skills, with the recent addition of Dr. Hirschman to BBM, combined with the already impressive team at YMI will create significant value creation for all stake holders involved. We look forward to working with YMI and also on future acquisitions of promising pharmaceuticals." Dr. Shalom Z. Hirschman, consultant to BBM leading its acquisition program, added, "A creative approach to the clinical development of YMI's most promising chemotherapeutic agents can add great benefit to the treatment of particular neoplasms and enhance shareholder value. The science underlying YMI's products meshes very well with the technology recently acquired by BBM."
The full text of the offer letter was filed by BBM in a Form 8-K today.
About BBM Holdings:
BBM Holdings (OTC Bulletin Board: BBMO) has been exploring acquisition possibilities. It was formerly a telecommunications engineering and service company.
This press release contains statements that constitute "forward-looking
statements" as that term is defined in the Securities Reform Act of 1995
(the "Reform Act"). Investors are cautioned that forward-looking statements
involve risks and uncertainties that could cause actual results to differ
materially from the statements. Factors that may cause or contribute to
such differences include, among other things, failure of our acquisition
program, inability to
'/>"/>
| SOURCE BBM Holdings Copyright©2008 PR Newswire. All rights reserved |